ATE395917T1 - Kombination von docetaxel mit flavopiridol - Google Patents

Kombination von docetaxel mit flavopiridol

Info

Publication number
ATE395917T1
ATE395917T1 AT02737950T AT02737950T ATE395917T1 AT E395917 T1 ATE395917 T1 AT E395917T1 AT 02737950 T AT02737950 T AT 02737950T AT 02737950 T AT02737950 T AT 02737950T AT E395917 T1 ATE395917 T1 AT E395917T1
Authority
AT
Austria
Prior art keywords
flavopiridol
docetaxel
combination
Prior art date
Application number
AT02737950T
Other languages
English (en)
Inventor
Marie-Christine Bissery
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Application granted granted Critical
Publication of ATE395917T1 publication Critical patent/ATE395917T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT02737950T 2001-03-23 2002-03-22 Kombination von docetaxel mit flavopiridol ATE395917T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27794801P 2001-03-23 2001-03-23
US30269201P 2001-07-05 2001-07-05
US33491601P 2001-12-04 2001-12-04

Publications (1)

Publication Number Publication Date
ATE395917T1 true ATE395917T1 (de) 2008-06-15

Family

ID=27402954

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02737950T ATE395917T1 (de) 2001-03-23 2002-03-22 Kombination von docetaxel mit flavopiridol

Country Status (33)

Country Link
US (2) US20020182204A1 (de)
EP (1) EP1372652B1 (de)
JP (1) JP2004521140A (de)
KR (1) KR100879712B1 (de)
CN (1) CN1498107A (de)
AR (1) AR034222A1 (de)
AT (1) ATE395917T1 (de)
AU (1) AU2002312815B2 (de)
BR (1) BR0208221A (de)
CA (1) CA2441441C (de)
CY (1) CY1110449T1 (de)
CZ (1) CZ301423B6 (de)
DE (1) DE60226710D1 (de)
DK (1) DK1372652T3 (de)
EA (1) EA007815B1 (de)
ES (1) ES2305253T3 (de)
HR (1) HRPK20030766B3 (de)
HU (1) HU229258B1 (de)
IL (2) IL158058A0 (de)
ME (1) MEP16408A (de)
MX (1) MXPA03007743A (de)
NO (1) NO332441B1 (de)
NZ (1) NZ527655A (de)
PE (1) PE20020907A1 (de)
PL (1) PL206118B1 (de)
PT (1) PT1372652E (de)
RS (1) RS50681B (de)
SI (1) SI1372652T1 (de)
SK (1) SK287481B6 (de)
TW (1) TWI355935B (de)
UY (1) UY27220A1 (de)
WO (1) WO2002076484A2 (de)
ZA (1) ZA200307381B (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003217982A1 (en) * 2002-03-06 2003-09-22 The Medical Research And Education Trust Botanical extract compositions with anti-cancer or phytoestrogenic activity comprising wogonin, isoliquiritigenin and/or coumestrol
AU2003287081A1 (en) * 2002-10-16 2004-05-04 Ilex Products, Inc. Clofarabine and taxane chemotherapy combination
BR0316010A (pt) * 2002-11-06 2005-09-13 Cyclacel Ltd Combinação
BRPI0707580A2 (pt) * 2006-02-10 2011-05-10 Nerviano Medical Sciences Srl combinaÇÕes compreendendo um inibidor cdk e um anticorpo do fator de crescimento ou antimitàtico
MX2013005661A (es) * 2010-11-19 2013-09-13 Piramal Entpr Ltd Combinacion farmaceutica de paclitaxel y un inhibidor cdk (quinasa dependiente de ciclina).
SG193505A1 (en) * 2011-04-01 2013-10-30 Astrazeneca Ab Therapeutic treatment
AU2012321110B2 (en) 2011-11-30 2014-10-23 Astrazeneca Ab Combination treatment
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
MX9102128A (es) * 1990-11-23 1992-07-08 Rhone Poulenc Rorer Sa Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
AU2195297A (en) * 1996-02-20 1997-09-02 Sloan-Kettering Institute For Cancer Research Combinations of pkc inhibitors and therapeutic agents for treating cancers

Also Published As

Publication number Publication date
PL367702A1 (en) 2005-03-07
US20020182204A1 (en) 2002-12-05
SK287481B6 (sk) 2010-11-08
HUP0303589A3 (en) 2007-05-02
AU2002312815B2 (en) 2006-08-24
PL206118B1 (pl) 2010-07-30
MXPA03007743A (es) 2004-11-12
TWI355935B (en) 2012-01-11
CY1110449T1 (el) 2015-04-29
DE60226710D1 (de) 2008-07-03
HU229258B1 (en) 2013-10-28
YU69503A (sh) 2006-08-17
HUP0303589A2 (hu) 2004-03-01
IL158058A (en) 2010-02-17
NO20034124L (no) 2003-09-16
EP1372652B1 (de) 2008-05-21
CA2441441C (en) 2009-05-26
HRPK20030766B3 (en) 2006-11-30
DK1372652T3 (da) 2008-09-22
PT1372652E (pt) 2008-07-24
AR034222A1 (es) 2004-02-04
SK11692003A3 (sk) 2004-03-02
BR0208221A (pt) 2004-03-02
EA007815B1 (ru) 2007-02-27
CZ20032551A3 (en) 2004-07-14
KR100879712B1 (ko) 2009-01-22
KR20030086318A (ko) 2003-11-07
EP1372652A2 (de) 2004-01-02
NO20034124D0 (no) 2003-09-16
NO332441B1 (no) 2012-09-17
US20060128640A1 (en) 2006-06-15
UY27220A1 (es) 2002-09-30
NZ527655A (en) 2006-03-31
SI1372652T1 (sl) 2008-10-31
CN1498107A (zh) 2004-05-19
ES2305253T3 (es) 2008-11-01
IL158058A0 (en) 2004-03-28
CZ301423B6 (cs) 2010-02-24
RS50681B (sr) 2010-06-30
HRP20030766A2 (en) 2005-06-30
CA2441441A1 (en) 2002-10-03
WO2002076484A2 (en) 2002-10-03
ZA200307381B (en) 2005-03-30
JP2004521140A (ja) 2004-07-15
WO2002076484A3 (en) 2003-01-03
EA200301053A1 (ru) 2004-02-26
PE20020907A1 (es) 2002-12-19
MEP16408A (en) 2010-10-10

Similar Documents

Publication Publication Date Title
DE60230173D1 (de) Presbyopiekorrektur
ATE402148T1 (de) Substituierte pyridinylamine
ATE524462T1 (de) C5-modifizierte indazolylpyrrolotriazine
DE50206892D1 (de) Substituierte imidazotriazinone
DE50212455D1 (de) Verwendung von Dimerdiolen
ATE335486T1 (de) Hydrazono-malonitrile
ATE428695T1 (de) Spirocyclische 3-phenyl-3-substituierte-4- ketolaktame und -laktone
DK1373228T3 (da) Substituerede fluoralkoxyphenylsulfonylurinstoffer
DE50204794D1 (de) Kugelgelenk
ATE435197T1 (de) Substituierte 4-aminocyclohexanole
ATE395917T1 (de) Kombination von docetaxel mit flavopiridol
DE60123416D1 (de) Refiner
DE60234481D1 (de) Verschachtelungsverfahren
DE60007360D1 (de) Amorphe modifikation von torasemid
NO20022722D0 (no) Pseudo-offset migrering
ATE299873T1 (de) Substituierte c-furan-2-yl-methylamin- und c- thiophen-2-yl-methylamin-derivate
ATE319694T1 (de) Phenylalkyne
DE50211807D1 (de) Schiebernadel
DE60110464D1 (de) Federball
DE60219418T8 (de) Silanylphenole und -naphthole
ATE354561T1 (de) Substituierte 1-aryl-but-3-enylamin- und 1-aryl- but-2-enylaminverbindungen
DE60216967D1 (de) Substituierte cyclohexanderivate
AT500276B8 (de) Radschwenksystem
ATA7462001A (de) Radspannwerk
DE60233601D1 (de) Verwendung von bestimmten Cyclolignanen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1372652

Country of ref document: EP